Evolution of HER-2 Targeted Therapies

  • The development of the monoclonal antibody trastuzumab (Herceptin):
    • Has revolutionized the treatment of patients with HER-2-positive breast cancer
  • The exact mechanism of action of trastuzumab remains unclear:
    • It is postulated that its action includes:
      • Antibody-dependent cellular toxicity
      • Inhibition of cell cycle progression
      • Antiangiogenic effects
  • The use of trastuzumab was first approved by the Food and Drug Administration (FDA) in 1998 for the treatment of HER-2-positive metastatic disease:
    • Since that time, drug testing progressed to the adjuvant and neoadjuvant settings
    • Today, trastuzumab is regarded as the standard of care for patients with HER-2-positive breast cancer.
  • Other agents include:
    • The small-molecule tyrosine kinase inhibitor lapatinib
    • Pertuzumab
    • Trastuzumab-emtansine
    • Neratinib
    • Ertumaxomab

#Arrangoiz #CancerSurgeon #BreastSurgeon #SurgicalOncologist #BreastCancer #HERPositiveBreasrtCancer #CASO #CenterforAdvancedSurgicalOncology

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s